Fair Value Measurements - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Payments related to the settlement of the contingent consideration liability, Financing activities	$ 32,918,000	$ 10,665,000	$ 13,100,000
Payments related to the settlement of the contingent consideration liability, Operating activities	1,800,000
Impairment of intangible assets	$ 1,700,000	$ 1,600,000	$ 28,700,000
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]	Asset Impairment Charges	Asset Impairment Charges	Asset Impairment Charges
Loss (gain) on disposition of business	$ 1,417,000		$ (517,000)
Impairment loss on operating lease asset	0	$ 1,400,000	1,500,000
Impairment of equity method investment		0
Interest income	439,000	769,000	604,000
Investments in privately held companies	15,576,000	14,711,000
Impairment of property and equipment	0
Long-term notes receivable, net	2,397,000	2,345,000
Allowance for expected credit losses	281,000	199,000	730,000
NinePoint Medical, Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment of property and equipment			$ 359,000
Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]			Asset Impairment Charges
Bluegrass Vascular Technologies, Inc
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Payment received on entire principal balance and all accrued interest		2,800,000
XableCath
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment of equity method investment	500,000
Fusion Medical, Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment of equity method investment			$ 2,500,000
Ownership percentage			19.50%
Bluegrass Vascular Technologies, Inc
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment of equity method investment			$ 3,500,000
STD Pharmaceutical Products Limited
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment of intangible assets	$ 1,700,000		$ 8,200,000
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]	Asset Impairment Charges		Asset Impairment Charges
Selio
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term notes receivable, net	$ 2,400,000	2,300,000
Allowance for expected credit losses	281,000	199,000
ArraVasc Limited
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment of intangible assets		$ 1,600,000	$ 4,800,000
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]		Asset Impairment Charges	Asset Impairment Charges
Impairment of property and equipment		$ 1,300,000
Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]		Asset Impairment Charges
Director | Cianna Medical
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent payments related to acquisition	1,600,000	$ 800,000
Other long-term obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability, noncurrent	2,300,000	13,500,000
Accrued expenses
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability, current	$ 15,800,000	$ 34,700,000